8.30 - 8.45

Welcome

Part 5 - New development in Proteomic for clinical studies

8.45 - 9.30	Plenary lecture
	Beyond Serum Proteomics: Application of MALDI MS Imaging, Glycoproteomic and Quantitative Proteomic Methodologies to Tissues and Proximal Prostatic Fluids for Prostate Cancer Biomarkers
	RR Drake (USA)

9.30	Biomarker harvesting using Innovative micro-nanoproteomic at the bedside
	F Berger (France)
10.00	Tentative strategies for the translation of “omics”-technologies into innovative biomarkers
	J Garin (France)

10.30 - 11.00	Coffee break – Visit of exhibition - Posters

11.00	Autoantibodies to α-enolase isoforms as diagnostic and prognostic markers in pancreatic cancer
	B Tomaino (Italy)
11.15	Depletion of high-abundance proteins in proteomic clinical studies
	P Ducoroy (France)
11.45	Peptides OFFGEL electrophoresis: a suitable pre-analytical step for complex eukaryotic samples fractionation compatible with quantitative iTRAQ labeling
	M Seve (France)
12.15	Proteomics-based identification of HSP60 as atumor antigen in early-stage breast cancer
	C Desmetz (France)

12.30 - 13.40	Lunch – Visit of exhibition - Posters

Part 5.2 - Micro arrays and proteomic

13.40	Protein arrays as tools for discovery of serum autoantibody markers in cancer
	D Murphy (Ireland)
14.10	Design of recombinant antibody microarrays for high-throughput oncoproteomics
	C Wingren (Sweden)
14.40	SPR-MS: Surface Plasmon Resonance - Mass Spectrometry in proteomic studies
	W Boireau (France)
15.10	SOCS2, an ubiquitin ligase with tumor suppressor functions in prostate cancer
	D Iglesias-Gato (Sweden)

15.25 - 15.45	Coffee break – Visit of exhibition - Posters

Part 5.3 - Imaging MS

15.45	Molecular Imaging of Tissue Sections by MALDI MS: Applications in Cancer Research
	P Chaurand (USA)
16.15	Proteomic Imaging in clinical studies
	M Salzet (France)
16.45	Global analysis and identification of hepatocellular carcinoma associated proteins or peptides by mass spectrometry
	TC Lai (Taiwan)

17.00	End of the conference